SENESTECH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7285 USD | -2.84% |
|
+1.48% | -42.64% |
| Sales 2024 * | 2.25M 188M | Sales 2025 * | 4.51M 376M | Capitalization | 3.75M 312M |
|---|---|---|---|---|---|
| Net income 2024 * | -6M -500M | Net income 2025 * | -6M -500M | EV / Sales 2024 * | 1.66 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.83 x |
| P/E ratio 2024 * |
-1.1
x | P/E ratio 2025 * |
-1.66
x | Employees | 25 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.96% |
More Fundamentals
* Assessed data
More news
Latest transcript on SenesTech, Inc.
More press releases
| 1 day | -2.84% | ||
| 1 week | +1.48% | ||
| Current month | +6.74% | ||
| 1 month | +4.37% | ||
| 3 months | -6.72% | ||
| 6 months | -80.42% | ||
| Current year | -42.64% |
1 week
0.70
0.78
1 month
0.620.95
Current year
0.621.78
1 year
0.5219.20
3 years
0.52460.80
5 years
0.529 360.00
10 years
0.5251 288.01
| Managers | Title | Age | Since |
|---|---|---|---|
Joel Fruendt
CEO | Chief Executive Officer | 63 | 15/22/15 |
| Director of Finance/CFO | 64 | 01/15/01 | |
Dan Palasky
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Matthew Szot
BRD | Director/Board Member | 50 | 01/15/01 |
Jacob Leach
BRD | Director/Board Member | 46 | 05/20/05 |
| Chairman | 51 | 01/18/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 0.7285 | -2.84% | 27,758 |
| 25/24/25 | 0.7498 | -1.50% | 36,699 |
| 24/24/24 | 0.7612 | +2.73% | 20,446 |
| 23/24/23 | 0.741 | -0.31% | 35,481 |
| 22/24/22 | 0.7433 | +3.54% | 29,710 |
Delayed Quote Nasdaq, April 27, 2024 at 02:00 am IST
More quotes
SenesTech, Inc. develops and commercializes products for managing animal pest populations, initially rat populations, through fertility control. The Company has two product lines of fertility control products: ContraPest and Evolve. Its product ContraPest, is a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide (VCD) and triptolide. ContraPest targets the reproductive systems of both male and female Norway and roof rats beginning with the first breeding cycle following consumption, which can lead to sustained reductions of the rat population. ContraPest is a highly palatable liquid formulation that reduces fertility in both male and female rats. Additionally, ContraPest does not cause illness in rats, and, therefore, it does not change behavior or result in bait aversion. ContraPest offers a new tool used in coordination with rodenticides as part of an integrated pest management program. The Company's technology can also be applied to other mammalian species.
Calendar
09/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.7285
USD
Average target price
3.5
USD
Spread / Average Target
+380.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -42.64% | 3.75M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- SNES Stock
